Show simple item record

dc.contributor.authorMarín López, Alejandro
dc.contributor.authorCalvo Pinilla, Eva
dc.contributor.authorBarriales, Diego
dc.contributor.authorLorenzo, Gema
dc.contributor.authorBenavente Martínez, Francisco Javier
dc.contributor.authorBrun, Alejandro
dc.contributor.authorMartínez Costas, José Manuel
dc.contributor.authorOrtego, Javier
dc.date.accessioned2019-03-29T14:23:08Z
dc.date.available2019-03-29T14:23:08Z
dc.date.issued2017-06
dc.identifier.citationMarín-López, A., Calvo-Pinilla, E., Barriales, D., Lorenzo, G., Benavente, J., & Brun, A. et al. (2017). Microspheres-prime/rMVA-boost vaccination enhances humoral and cellular immune response in IFNAR(−/−) mice conferring protection against serotypes 1 and 4 of bluetongue virus. Antiviral Research, 142, 55-62. doi: 10.1016/j.antiviral.2017.03.010
dc.identifier.issn0166-3542
dc.identifier.urihttp://hdl.handle.net/10347/18497
dc.description.abstractBluetongue virus (BTV) is the causative agent of bluetongue disease (BT), which affects domestic and wild ruminants. At the present, 27 different serotypes have been documented. Vaccination has been demonstrated as one of the most effective methods to avoid viral dissemination. To overcome the drawbacks associated with the use of inactivated and attenuated vaccines we engineered a new recombinant BTV vaccine candidate based on proteins VP2, VP7, and NS1 of BTV-4 that were incorporated into avian reovirus muNS-Mi microspheres (MS-VP2/VP7/NS1) and recombinant modified vaccinia virus Ankara (rMVA). The combination of these two antigen delivery systems in a heterologous prime-boost vaccination strategy generated significant levels of neutralizing antibodies in IFNAR(−/−) mice. Furthermore, this immunization strategy increased the ratio of IgG2a/IgG1 in sera, indicating an induction of a Th1 response, and elicited a CD8 T cell response. Immunized mice were protected against lethal challenges with the homologous serotype 4 and the heterologous serotype 1 of BTV. All these results support the strategy based on microspheres in combination with rMVAs as a promising multiserotype vaccine candidate against BTV
dc.description.sponsorshipThis work was supported by grants from the Spanish Ministerio de Economía y Competitividad (AGL2011-23506, AGL-2014-57430-R and BFU2013-43513-R). Financial support from the Consellería de Cultura, Educación e Ordenación Universitaria (Centro singular de investigación de Galicia accreditation 2016–2019, ED431G/09) and the European Regional Development Fund (ERDF), is also gratefully acknowledged
dc.language.isoeng
dc.publisherElsevier
dc.relationinfo:eu-repo/grantAgreement/MINECO/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/BFU2013-43513-R/ES/REOVIRUS AVIAR: FACTORES DE VIRULENCIA Y NUEVAS DIANAS TERAPEUTICAS
dc.relationinfo:eu-repo/grantAgreement/MICINN/Plan Nacional de I+D+i 2008-2011/AGL2011-23506/ES/DESARROLLO DE VACUNAS DIVA DE NUEVA GENERACION QUE CONFIERAN PROTECCION CRUZADA FRENTE A DISTINTOS SEROTIPOS DE LOS ORBIVIRUS LENGUA AZUL Y PESTE EQUINA AFRICANA
dc.relationinfo:eu-repo/grantAgreement/MINECO/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/AGL2014-57430-R/ES/ MEJORA Y EVALUACION DE VACUNAS BASADAS EN VECTORES VIRICOS Y MICROPARTICULAS FRENTE A ORBIVIRUS Y BUNYAVIRUS TRANSMITIDOS POR ARTROPODOS: HACIA EL DESARROLLO DE VACUNAS MULTIV
dc.rights© 2017 Elsevier B.V. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectBluetongue
dc.subjectMicrospheres
dc.subjectMVA
dc.subjectMultiserotype
dc.subjectVaccine
dc.titleMicrospheres-prime/rMVA-boost vaccination enhances humoral and cellular immune response in IFNAR(−/−) mice conferring protection against serotypes 1 and 4 of bluetongue virus
dc.typeinfo:eu-repo/semantics/article
dc.identifier.DOI10.1016/j.antiviral.2017.03.010
dc.relation.publisherversionhttps://doi.org/10.1016/j.antiviral.2017.03.010
dc.type.versioninfo:eu-repo/semantics/acceptedVersion
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.contributor.affiliationUniversidade de Santiago de Compostela. Centro de Investigación en Química Biolóxica e Materiais Moleculares
dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Bioquímica e Bioloxía Molecular
dc.description.peerreviewedSI


Files in this item

application/pdf
Name: 2017_ortego_antiviralres_microspheres_vaccination.pdf
Size: 645.4 Kb
Format: PDF


Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2017 Elsevier B.V. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as  © 2017 Elsevier B.V. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/





Harvesters:Useful links:
Universidade de Santiago de Compostela | Teléfonos: +34 881 811 000 e +34 982 820 000 | Contact Us | Send Feedback